60966-36-1

Basic information

• Product Name: 21-hydroxy-20-methylpregn-4-en-3-one
• Synonyms: 21-hydroxy-20-methylpregn-4-en-3-one;20-(Hydroxymethyl)pregna-4-ene-3-one;20-Hydroxymethylpregn-4-en-3-one;Pregn-4-en-3-one, 21-hydroxy-20-methyl-
• CAS NO: 60966-36-1
• Molecular Formula: C₂₂H₃₄O₂
• Molecular Weight: 330.50416
• EINECS: 262-543-1
• Mol File: 60966-36-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 464.1°C at 760 mmHg
• Flash Point: 197.5°C
• Appearance: /
• Density: 1.07g/cm³
• Vapor Pressure: 1.45E-10mmHg at 25°C
• Refractive Index: 1.546
• PKA: 14.97±0.10(Predicted)
• CAS DataBase Reference: 21-hydroxy-20-methylpregn-4-en-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 21-hydroxy-20-methylpregn-4-en-3-one(60966-36-1)
• EPA Substance Registry System: 21-hydroxy-20-methylpregn-4-en-3-one(60966-36-1)

Safety Data

• Hazardous Substances Data: 60966-36-1(Hazardous Substances Data)

Usage

Description

21-Hydroxy-20-methylpregn-4-en-3-one is a steroidal compound derived from the steroid hormone progesterone, which is produced by the corpus luteum and plays a crucial role in the menstrual cycle and pregnancy. It is characterized by the presence of a hydroxyl group at the 21st position and a methyl group at the 20th position, attached to the pregnane nucleus. 21-hydroxy-20-methylpregn-4-en-3-one is known to have various biological activities and is used in different applications across various industries.

Uses

Used in Pharmaceutical Industry:
21-Hydroxy-20-methylpregn-4-en-3-one is used as a pharmaceutical intermediate for the synthesis of various steroidal drugs. It serves as a key building block in the production of corticosteroids, which have anti-inflammatory and immunosuppressive properties, and are used to treat a wide range of conditions, including allergies, asthma, and autoimmune diseases.
Used in Hormone Replacement Therapy:
21-Hydroxy-20-methylpregn-4-en-3-one is used as a hormone precursor in hormone replacement therapy (HRT) for women experiencing menopause. It helps in maintaining the hormonal balance and alleviates symptoms such as hot flashes, night sweats, and vaginal dryness.
Used in Veterinary Medicine:
21-Hydroxy-20-methylpregn-4-en-3-one is used as a veterinary drug to induce estrus and synchronize ovulation in livestock, improving reproductive efficiency and overall productivity in the agricultural industry.
Used in Research and Development:
21-Hydroxy-20-methylpregn-4-en-3-one is used as a research compound in the development of new drugs and therapies targeting various diseases and conditions. Its unique structure and biological activities make it a valuable tool for understanding the mechanisms of action of steroid hormones and their potential applications in medicine.

InChI:InChI=1/C22H34O2/c1-14(13-23)18-6-7-19-17-5-4-15-12-16(24)8-10-21(15,2)20(17)9-11-22(18,19)3/h12,14,17-20,23H,4-11,13H2,1-3H3/t14?,17-,18+,19-,20-,21-,22+/m0/s1

Upstream product

• 24254-01-1 20β-carboxyaldehyde-4-pregnen-3-one 
• 3986-89-8 (20S)-3-oxopregn-4-ene-20-carboxaldehyde 

Downstream Products

• 24377-48-8 22-(piperidin-1-yl)-23,24-dinorchola-4,20⁽²²⁾-dien-3-one 
• 57-83-0 Progesterone 

Relevant articles and documents

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

Steriod 5-alpha-reductase inhibitors

Invented are substituted acrylate analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5-α-reductase. Also invented are intermediates used in preparing these compounds.

PHOSPHINIC ACID SUBSTITUTED STEROIDS AS INHIBITORS OF STEROID 5 ALPHA-REDUCTASE

The invention relates to 3-phosphinic acid steroidal compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds to inhibit steroid 5alpha-reductase.